header logo image


Page 58«..1020..57585960..70..»

Archive for the ‘Biotechnology’ Category

Cellect Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2016 Financial Results – P&T Community

Friday, March 24th, 2017
Cellect Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2016 Financial Results
P&T Community
TEL AVIV, Israel, March 23, 2017 (GLOBE NEWSWIRE) -- Cellect Biotechnology Ltd. (NASDAQ:APOP) (TASE:APOP), a developer of innovative technology which enables the functional selection of stem cells, today provided a corporate update and ...

and more »

Visit link:
Cellect Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2016 Financial Results - P&T Community

Read More...

CEEB 2017: Applications released for MSc, MTech Biotechnology courses, check here – The Indian Express

Friday, March 24th, 2017

By: Express Web Desk | New Delhi | Published:March 24, 2017 12:07 pm CEEB 2017: The details of the course under each university is provided in three prospectus available on the official website

CEEB 2017: The Jawaharlal Nehru University (JNU), Delhi has announced that it will hold The Combined Entrance Examination (CEEB) 2017 for MSc in Biology, MSc in Agricultural Biotechnology and MTech in Biotechnology will be held on May 19, 2017. Candidates who are interested in the courses can apply online from JNUs official website.

The exam is being held by JNU on behalf of 14 universities that offer Agricultural Biotechnology, 32 that offer Biotechnology and six institutes offering MTech in Biotechnology. The details of the course under each university is provided in three prospectus available on the official website along with the fees to be paid at the time of admission. Candidates can also check the eligibility requirements for each college provided in the prospectus.

Steps to apply for CEEB 2017:

Go to the official website for JNU (jnu.ac.in).

Click on the admissions tab on the home page.

Click on the notification Combined Entrance Examination for Biotechnology Programmes [ CEEB ] Prospectus 2017-18 and read the prospectus provided for each course. Make sure to check all details before proceeding.

On the admissions page, click on Apply online and follow the link for CEEB.

Read the instructions carefully and click on I Accept Apply Online.

Fill in the details in the fields provided and click on Register.

Download a copy of the application form for further reference.

For more stories on CEEB 2017, click here

For all the latest Education News, download Indian Express App now

The Indian Express Online Media Pvt Ltd

Read the original here:
CEEB 2017: Applications released for MSc, MTech Biotechnology courses, check here - The Indian Express

Read More...

Biotechnology | FAO | Food and Agriculture Organization of …

Wednesday, March 22nd, 2017

Agricultural biotechnologies are being applied to an increasing extent in crops, livestock, forestry, fisheries and aquaculture and agro-industries, to alleviate hunger and poverty, assist in adaptation to climate change and maintain the natural resource base.

They have not sufficiently benefited smallholder farmers and producers and consumers. More research and developmentof agricultural biotechnologies should be focused on the needs of smallholders.

In order to produce food in a sustainable way for an additional 2 billion people by 2050, a business-as-usual approach will not be sufficient.

This is especially true in the face of climate change and other forces threatening natural resources like biodiversity, land and water that are essential for food production and agriculture, including forestry and fisheries.

To meet these challenges, science and the application of biotechnologies as well as conventional technologies will play a key role.

FAO recognizes that when appropriately integrated with other technologies for the production of food, agricultural products and services, biotechnology can be of significant assistance in meeting the needs of an expanding and increasingly urbanized population. Regarding biotechnology, FAO assists its Member countries and their institutions by:

Read more from the original source:
Biotechnology | FAO | Food and Agriculture Organization of ...

Read More...

Biotechnology Gets A Shot In the Arm – Focus on Funds – Barrons.com – Barron’s (blog)

Wednesday, March 22nd, 2017
Biotechnology Gets A Shot In the Arm - Focus on Funds - Barrons.com
Barron's (blog)
The healthcare sector has been doing rather well, gaining 8.9% year-to-date. Behind just information technology, healthcare stocks have outpaced Trump ...
iShares Nasdaq Biotechnology (IBB) volatility low into Credit Suisse ...StreetInsider.com
iShares NASDAQ Biotechnology Index (IBB) Rating Increased to ...BBNS

all 5 news articles »

Read more here:
Biotechnology Gets A Shot In the Arm - Focus on Funds - Barrons.com - Barron's (blog)

Read More...

BIO Announces Plenary Sessions for 2017 World Congress on Industrial Biotechnology – Business Wire (press release)

Wednesday, March 22nd, 2017

WASHINGTON--(BUSINESS WIRE)--The Biotechnology Innovation Organization (BIO) today released the list of speakers for plenary programs at the2017 World Congress on Industrial Biotechnology. The sessions will feature executives from the biofuels, household and personal care, and airline industries who will discuss technology breakthroughs, business partnerships and sustainability initiatives. The worlds largest industrial biotechnology event will be held July 23-26, 2017 at the Palais des congrs de Montral in Montral, Qubec, Canada.

Brent Erickson, Executive Vice President, Industrial and Environmental at BIO, stated, The Plenary Program for the 2017 World Congress will cover several novel topics that are emerging within the industry. Panelists will provide an overview of the current state of biobased food ingredients, flavorings, and personal care products and where market trends are headed in the future. Additionally, industry representatives and trade reporters will discuss how to meaningfully communicate about the biobased economy.

Some highlighted Plenary Sessions include:

Biotech and the Future of Food Ingredients, Flavorings, and Personal Care Monday, July 24, 2017 3:45 pm - 5:00pm

Speakers:

Second Generation Biofuels Poised for Big Wins Tuesday, July 25, 2017 8:30 am - 10:00am

Moderator:Jim Lane, Editor and Publisher, The Digest Speakers:

Effectively Communicating the Benefits of Industrial Biotechnology Tuesday, July 25, 2017 11:45 am 1:30 pm

Moderator:Rebecca Coons, Senior Editor, Chemical Week, IHS Chemical Speakers:

All programs at the World Congress on Industrial Biotechnology are open to attendance by members of the media. Complimentarymedia registrationis available to editors and reporters working full time for print, broadcast or web publications with valid press credentials.

For more information on the conference please visithttp://www.bio.org/worldcongress. For assistance, please contactworldcongress@bio.org.

About BIO

BIO is the world's largest trade association representing biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. BIO also produces theBIO International Convention, the worlds largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world.BIOtechNOWis BIO's blog chronicling innovations transforming our world and the BIO Newsletter is the organizations bi-weekly email newsletter.Subscribe to the BIO Newsletter.

Upcoming BIO Events

BIO-Europe Spring Conference March 20-22, 2017 Barcelona, Spain

BIO IP Counsels Committee Conference March 27-29, 2017 Newport Beach, CA

BIO International Convention June 19-22, 2017 San Diego, CA

BIO World Congress on Industrial Biotechnology July 23 - 26, 2017 Montral, Canada

Read this article:
BIO Announces Plenary Sessions for 2017 World Congress on Industrial Biotechnology - Business Wire (press release)

Read More...

Analytical Guide for Puma Biotechnology, Inc. (PBYI), Liberty … – The USA Commerce

Wednesday, March 22nd, 2017

The USA Commerce
Analytical Guide for Puma Biotechnology, Inc. (PBYI), Liberty ...
The USA Commerce
The relative strength index or RSI highlights overbought (above 70) and oversold (below 30) areas. The current value of the RSI is 53.11 that is neither bought ...

and more »

Go here to read the rest:
Analytical Guide for Puma Biotechnology, Inc. (PBYI), Liberty ... - The USA Commerce

Read More...

Puma Biotechnology Inc (PBYI) Plunges 9.45% on March 21 – Equities.com

Tuesday, March 21st, 2017

Market Summary Follow

Puma Biotechnology Inc is a A biopharmaceutical company

PBYI - Market Data & News

PBYI - Stock Valuation Report

Puma Biotechnology Inc (PBYI) had a rough trading day for Tuesday March 21 as shares tumbled 9.45%, or a loss of $-4.2 per share, to close at $40.25. After opening the day at $44.75, shares of Puma Biotechnology Inc traded as high as $44.85 and as low as $39.80. Volume was 947,068 shares over 8,315 trades, against an average daily volume of 991,915 shares and a total float of 36.95 million.

As a result of the decline, Puma Biotechnology Inc now has a market cap of $1.49 billion. In the last year, shares of Puma Biotechnology Inc have traded between a range of $73.27 and $19.74, and its 50-day SMA is currently $36.22 and 200-day SMA is $42.55.

For a complete fundamental analysis of Puma Biotechnology Inc, check out Equities.coms Stock Valuation Analysis report for PBYI.

Want to invest with the experts? Subscribe to Equities Premium newsletters today! Visit http://www.equitiespremium.com/ to learn more about Guild Investments Market Commentary and Adam Sarhans Find Leading Stocks today.

Puma Biotechnology Inc is a biopharmaceutical company. It is engaged in the acquisition, development and commercialization of products to enhance cancer care.

Puma Biotechnology Inc is based out of Los Angeles, CA and has some 160 employees. Its CEO is Alan H. Auerbach.

Puma Biotechnology Inc is a component of the Russell 2000. The Russell 2000 is one of the leading indices tracking small-cap companies in the United States. It's maintained by Russell Investments, an industry leader in creating and maintaining indices, and consists of the smallest 2000 stocks from the broader Russell 3000 index.

Russell's indices differ from traditional indices like the Dow Jones Industrial Average (DJIA) or S&P 500, whose members are selected by committee, because they base membership entirely on an objective, rules based methodology. The 3,000 largest companies by market cap make up the Russell 3000, with the 2,000 smaller companies making up the Russell 2000. It's a simple approach that gives a broad, unbiased look at the small-cap market as a whole.

To get more information on Puma Biotechnology Inc and to follow the companys latest updates, you can visit the companys profile page here: PBYIs Profile. For more news on the financial markets and emerging growth companies, be sure to visit Equities.coms Newsdesk. Also, dont forget to sign-up for our daily email newsletter to ensure you dont miss out on any of our best stories.

All data provided by QuoteMedia and was accurate as of 4:30PM ET.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer

Read the original here:
Puma Biotechnology Inc (PBYI) Plunges 9.45% on March 21 - Equities.com

Read More...

Biodiversity, Biotechnology and Intellectual Property: their relevance for the development of Colombia – Lexology (registration)

Tuesday, March 21st, 2017

Biotechnology has emerged as one of the most forward-looking fields of science in recent decades, and a large number of nations have set their sights on it as a long-term development pillar, given its wide range of applications and the leapfrogging of current information technology, which allows to further exploit its potential.

Biotechnology has already proven to be an option for growth in multiple economic sectors, finding applications of high importance in sectors such as pharmaceuticals, food, veterinary, cosmetic, environmental, agricultural, energy, among others, which make it an opportunity for those developing countries in search of a boost for the progress of their economies.

It is then in biotechnology that a country like Colombia, which occupies the second place after Brazil in world biodiversity, with around 10% of the fauna and flora of the planet, can find possibilities of great impact for its economic growth and technological development. However, it is not a simple challenge if one takes into account the little investment that, unfortunately, is destined for R&D in the country. For example, according to World Bank data for the year 2014, Colombia allocated about 0.2% of GDP for this purpose, an amount significantly lower than the world average of about 2%, and much lower than the number one country in this regard, South Korea, which investment in R&D is above 4% of GDP.

In this manner, the government, academics and companies must work together to transform this enormous biodiversity into a factory of knowledge and innovation that translates into solutions to both local and global problems, which in the long term will allow to narrow the economic-technological gap between Colombia and the most developed countries in the world.

Thus, in the commitment to research in general as a driving force for development, and in particular concerning the emerging biotechnology, intellectual property plays a decisive role for its progress; this is due to the fact that tools for the protection of inventions, such as patents, greatly influence the decision of companies to invest or not their capital in a particular sector, and even more in biotechnology, which is undoubtedly one of those with highest cost in both R&D and product development and process design.

Hence, it is possible to evidence in different countries a closely related upward trend between R&D spending and the filing of patent applications, making them a clear indicator of a country's innovation and inventive step. By way of example, this is clearly visible when comparing the number of patent applications filed in Colombia and South Korea, using data provided by the World Bank in this regard for the same year mentioned above. In Colombia, in 2014, 260 patent applications were filed by residents and 1898 by non-residents; values much lower than those in South Korea where the numbers amount to 164073 patent applications filed by residents and 46219 by non-residents for the same year.

Therefore, it is necessary a vision change from the government of Colombia that promotes the injection of public and private capital in R&D, which is supported by an intellectual property system that provides adequate legal protection to the inventions and compensates the economic efforts made in innovation. Taking into account the characteristics of the country, Colombia has the potential to establish, as one of the pillars of its economy, its own biodiversity together with biotechnology; however, to this day, this latter is greatly underestimated.

In this sense, the challenge for Colombia in the coming years is to recognize and take advantage of the immense potential for scientific research that it possesses, especially in terms of biotechnology, in order to have in the future the ability to offer products and services with high standards of quality and added value, derived from a sustainable exploitation of its natural resources that goes hand in hand with policies ensuring the technical, legal and economic conditions conducive to its realization.

Continue reading here:
Biodiversity, Biotechnology and Intellectual Property: their relevance for the development of Colombia - Lexology (registration)

Read More...

Assessing biotechnology in the age of cloud computing – Cloud Tech

Tuesday, March 21st, 2017

In order to ensure that patient outcomes are constantly being improved upon it is important that the speed of change within the biotechnology sector occurs at an exponential rate. However, this continued drive for innovation puts immense pressure on IT departments to develop new technologies at speed, while also making sure that they do this cost effectively.

Add to this the fact that, more so than other industries, biotech firms are extremely tightly regulated. As a result, IT groups within this industry are often reluctant to introduce more complexity into what is already a very complex environment. To them, expanding a data centre can often feel a whole lot easier than navigating the regulations of the cloud. Despite this, growth in the demand for cloud computing in life sciences research and development is escalating due to the benefits it brings to the industry benefits like exceeding regulatory requirements, for example.

At iland, we have worked with many companies in the healthcare, life sciences and biotech industries. Therefore, we know from experience that the implementation of cloud computing in biotechnology empowers organisations with the control and flexibility needed to lead the way in both the research world as well as the businesses world. For example, we recently worked with a US based biotechnology organisation on their backup and disaster recovery (DR) strategy, and were able to drive global data centre consolidation with host-based replication to the iland cloud. As a result, their DR testing and auditing processes were greatly simplified and streamlined which drove significant cost savings as well as compliance assurance.

If you still need convincing here are three key benefits that we believe cloud brings to biotech organisations:

When the Human Genome Project began it was one of the most extensive research projects in the field to date costing billions of pounds and lasting over a decade. These days, thanks largely to cloud technology, it can bedone in just 26 hours. Things such as drug R&D, clinical research as well as a whole host of other areas have benefited just as much from the rapid growth of computational power. The better your technology is at crunching huge sets of data, the quicker you can innovate.

Cloud computing within the biotech sector can take big data analysis to the next level by means of performance, connectivity, on-demand infrastructure and flexible provisioning. Labs can also benefit from immense computing power without the cost and complexity of running big onsite server rooms. They can also scale up at will in order to make use of new research and ideas almost instantly.

Concerns have been voiced that so called scientific computing in the cloud may make results less reproducible. One concern is that cloud computing will be a computing 'black box' that obscures details needed to accurately interpret the results of computational analyses. In actual fact, by leveraging the application program interfaces (APIs) in the iland cloud, biotech customers are able to integrate cloud data back into on-premises IT systems to ensure that data analyses done in the cloud can be easily shared and consumed by other applications. Essentially, cloud computing services bring more players to the table to solve the giant puzzle. Its a win-win situation from an economic and patient standpoint, and several big name companies are jumping on the biotech cloud bandwagon.

Biotech companies need to maintain strong access and authentication controls, while also being able to collaborate easily.For this reason audit trails and other measures are often required to verify that information has not been improperly altered, and that good experimental and manufacturing procedures have been followed. At the same time biotechnologists need to be able to access and share data across multiple departments or even multiple companies.

Cloud computing in biotechnology makes this all possible. Theiland cloud, for instance, centralises data, ensuring security and data sovereignty while facilitating collaboration. It supports extensive user and role based access control, two-factor authentication and integrity monitoring to prevent improper access and changes. In addition to data encryption, vulnerability scanning and intrusion detection, these measures facilitate security and compliance, without disrupting the internal workflow.

Complex regulatory requirements and logistics combined with niche markets make efficiency paramount within biotechnology. Even minor mistakes as a result of sloppy process management can easily result in major issues. Real-time operational reporting dramatically improves efficiency, quality control and decision making, allowing organisations to react instantly to challenges and opportunities, both internal and external.

As well as enhanced billing visibility and resource management functions, the release of our latest Secure Cloud Services means that the iland cloud now includes on-demand security and compliance reports. This advanced cloud management functionality is designed to foster strategic, self-sufficient control of a cloud environment, optimising overall cloud usage and costs to drive business initiatives and growth.

Without a shadow of a doubt, cloud technology can help biotechnology companies build the future.From research and development to marketing, computing affects everything your organisation does. With rich experience in the biotech, healthcare and life sciences sector, you should talk to iland today to find out how our cloud hosting services can give you the power to develop at the speed of thought, not the speed of compliance or processing.

Read more: Why the cloud could hold the cure to diseases

Visit link:
Assessing biotechnology in the age of cloud computing - Cloud Tech

Read More...

Exploring the cloud laboratory: biotechnology and cloud computing – Information Age

Tuesday, March 21st, 2017

Cloud computing within the biotech sector can take big data analysis to the next level by means of performance, connectivity, on-demand infrastructure and flexible provisioning

The continued drive for innovation puts immense pressure on IT departments to develop new technologies at speed, while also making sure that they do this cost effectively.

Add to this the fact that, more so than other industries, biotech firms are extremely tightly regulated. As a result, IT groups within this industry are often reluctant to introduce more complexity into what is already a very complex environment.

To them, expanding a data centre can often feel a whole lot easier than navigating the regulations of the cloud. Despite this, growth in the demand for cloud computing in life sciences research and development is escalating due to the benefits it brings to the industry benefits like exceeding regulatory requirements, for example.

iland haveworked with many companies in the healthcare, life sciences and biotech industries. Therefore, it knowsfrom experience that the implementation of cloud computing in biotechnology empowers organisations with the control and flexibility needed to lead the way in both the research world as well as the businesses world.

>See also:10 trends that will influence cloud computing in 2017

For example, ilandrecently worked with a US based biotechnology organisation on their backup and disaster recovery (DR) strategy, and were able to drive global data centre consolidation with host-based replication to the cloud. As a result, itsDR testing and auditing processes were greatly simplified and streamlined which drove significant cost savings as well as compliance assurance.

If you still need convincing here are three additional key benefits that cloud brings to biotech organisations.

When the Human Genome Project began it was one of the most extensive research projects in the field to date costing billions of pounds and lasting over a decade.

These days, thanks largely to cloud technology, it can be done in just 26 hours. Things such as drug R&D, clinical research as well as a whole host of other areas have benefited just as much from the rapid growth of computational power. The better your technology is at crunching huge sets of data, the quicker you can innovate.

Cloud computing within the biotech sector can take big data analysis to the next level by means of performance, connectivity, on-demand infrastructure and flexible provisioning.

Labs can also benefit from immense computing power without the cost and complexity of running big onsite server rooms. They can also scale up at will in order to make use of new research and ideas almost instantly.

Concerns have been voiced that so called scientific computing in the cloud may make results less reproducible. One concern is that cloud computing will be a computing black box that obscures details needed to accurately interpret the results of computational analyses.

>See also:How cloud computing can transform the pharmaceutical industry

In actual fact, by leveraging the application program interfaces (APIs) in the iland cloud, biotech customers are able to integrate cloud data back into on-premises IT systems to ensure that data analyses done in the cloud can be easily shared and consumed by other applications.

Essentially, cloud computing services bring more players to the table to solve the giant puzzle. Its a win-win situation from an economic and patient standpoint, and several big name companies are jumping on the biotech cloud bandwagon.

Biotech companies need to maintain strong access and authentication controls, while also being able to collaborate easily. For this reason audit trails and other measures are often required to verify that information has not been improperly altered, and that good experimental and manufacturing procedures have been followed.

At the same time bio-technologists need to be able to access and share data across multiple departments or even multiple companies.

Cloud computing in biotechnology makes this all possible it centralises data, ensuring security and data sovereignty while facilitating collaboration.

It supports extensive user and role based access control, two-factor authentication and integrity monitoring to prevent improper access and changes. In addition to data encryption, vulnerability scanning and intrusion detection, these measures facilitate security and compliance, without disrupting the internal workflow.

Complex regulatory requirements and logistics combined with niche markets make efficiency paramount within biotechnology. Even minor mistakes as a result of sloppy process management can easily result in major issues.

Real-time operational reporting dramatically improves efficiency, quality control and decision making, allowing organisations to react instantly to challenges and opportunities, both internal and external.

>See also:Managed cloud: making the most out of public cloud computing

As well as enhanced billing visibility and resource management functions, the release of the vendors secure cloud services means that the itscloud now includes on-demand security and compliance reports.

This advanced cloud management functionality is designed to foster strategic, self-sufficient control of a cloud environment, optimising overall cloud usage and costs to drive business initiatives and growth.

Without a shadow of a doubt, cloud technology can help biotechnology companies build the future. From research and development to marketing, computing affects everything an organisation does.

Sourced by Monica Brink, director of marketing, iland

Original post:
Exploring the cloud laboratory: biotechnology and cloud computing - Information Age

Read More...

The Brokerages Set Puma Biotechnology Inc (PBYI) PT at $70.50 – Petro Global News 24

Tuesday, March 21st, 2017

Puma Biotechnology Inc (NYSE:PBYI) has earned an average recommendation of Hold from the eight analysts that are covering the company. One equities research analyst has rated the stock with a sell recommendation, three have issued a hold recommendation and four have given a buy recommendation to the company. The average 1-year target price among brokers that have updated their coverage on the stock in the last year is $70.50.

Several brokerages have recently weighed in on PBYI. Royal Bank of Canada reissued a sector perform rating and issued a $17.00 price objective (down from $48.00) on shares of Puma Biotechnology in a research report on Thursday, March 2nd. Stifel Nicolaus reissued a buy rating and issued a $88.00 price objective on shares of Puma Biotechnology in a research report on Wednesday, November 30th. Citigroup Inc reissued a buy rating and issued a $88.00 price objective on shares of Puma Biotechnology in a research report on Saturday, March 4th. Zacks Investment Research lowered shares of Puma Biotechnology from a buy rating to a hold rating in a research report on Tuesday, January 10th. Finally, Credit Suisse Group AG reissued an outperform rating on shares of Puma Biotechnology in a research report on Wednesday, January 18th.

Puma Biotechnology (NYSE:PBYI) opened at 44.15 on Tuesday. Puma Biotechnology has a 52-week low of $19.74 and a 52-week high of $73.27. The firms market capitalization is $1.63 billion. The firm has a 50-day moving average of $36.87 and a 200-day moving average of $43.70.

Puma Biotechnology (NYSE:PBYI) last issued its quarterly earnings data on Wednesday, March 1st. The biopharmaceutical company reported ($2.04) earnings per share for the quarter, missing the Thomson Reuters consensus estimate of ($1.92) by $0.12. On average, equities research analysts forecast that Puma Biotechnology will post ($8.32) EPS for the current fiscal year.

In related news, SVP Richard Paul Bryce sold 2,293 shares of the firms stock in a transaction dated Friday, January 20th. The shares were sold at an average price of $33.24, for a total transaction of $76,219.32. Following the transaction, the senior vice president now directly owns 29,237 shares of the companys stock, valued at $971,837.88. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Robert Charnas sold 3,008 shares of the firms stock in a transaction dated Wednesday, February 1st. The stock was sold at an average price of $31.83, for a total transaction of $95,744.64. Following the transaction, the insider now directly owns 28,461 shares in the company, valued at $905,913.63. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 15,503 shares of company stock worth $511,078. 22.70% of the stock is owned by insiders.

Institutional investors have recently added to or reduced their stakes in the company. UBS Asset Management Americas Inc. raised its position in Puma Biotechnology by 2.4% in the third quarter. UBS Asset Management Americas Inc. now owns 12,891 shares of the biopharmaceutical companys stock worth $864,000 after buying an additional 300 shares in the last quarter. California State Teachers Retirement System raised its position in Puma Biotechnology by 1.0% in the third quarter. California State Teachers Retirement System now owns 52,275 shares of the biopharmaceutical companys stock worth $3,505,000 after buying an additional 500 shares in the last quarter. BlackRock Investment Management LLC raised its position in Puma Biotechnology by 1.2% in the third quarter. BlackRock Investment Management LLC now owns 92,595 shares of the biopharmaceutical companys stock worth $6,208,000 after buying an additional 1,091 shares in the last quarter. Tower Research Capital LLC TRC raised its position in Puma Biotechnology by 253.3% in the third quarter. Tower Research Capital LLC TRC now owns 2,427 shares of the biopharmaceutical companys stock worth $163,000 after buying an additional 1,740 shares in the last quarter. Finally, Metropolitan Life Insurance Co. NY raised its position in Puma Biotechnology by 12.6% in the fourth quarter. Metropolitan Life Insurance Co. NY now owns 20,142 shares of the biopharmaceutical companys stock worth $618,000 after buying an additional 2,247 shares in the last quarter. 80.98% of the stock is currently owned by institutional investors and hedge funds.

Puma Biotechnology Company Profile

Puma Biotechnology, Inc is a biopharmaceutical company that focuses on the development and commercialization of products for the treatment of cancer. The Company focuses on in-licensing the global development and commercialization rights to over three drug candidates, including PB272 (neratinib (oral)), which the Company is developing for the treatment of patients with human epidermal growth factor receptor type 2 (HER2), positive breast cancer, and patients with non-small cell lung cancer, breast cancer and other solid tumors that have a HER2 mutation; PB272 (neratinib (intravenous)), which the Company is developing for the treatment of patients with advanced cancer, and PB357, which is an orally administered agent.

Originally posted here:
The Brokerages Set Puma Biotechnology Inc (PBYI) PT at $70.50 - Petro Global News 24

Read More...

The Minneapolis Medical Research Foundation Selects Goodwin … – PR Newswire (press release)

Tuesday, March 21st, 2017

"For over 15 years, Goodwin Biotechnology has been one of the pioneers in providing development services and GMP manufacturing of a broad portfolio of Antibody:Drug Conjugate (ADC) and Protein:Drug Conjugate (PDC) projects, including cytotoxic ADCs, Radio-Immunoconjugates, Antibody:Peptide Conjugates, Antibody:Dye Conjugates, PEGylated proteins, and other bioconjugates including Biobetters," said Muctarr Sesay, Ph.D., Chief Scientific Officer at Goodwin Biotechnology. "Our experience in Bioconjugation has resulted in several patents and publications, as well as proprietary processes that enable us to help our clients overcome some significant challenges in developing their next generation of bioconjugates. When including our experience in manufacturing vaccines for use in early- and late-stage clinical trials, we found the Minneapolis Medical Research Foundation project to be highly intriguing."

"This is not an unusual approach for us when we initiate a project because we collaborate with many of our clients in the early stages of proof of concept/development by empirically recommending the appropriate processes to create a viable ADC or PDC candidate," Dr. Sesay continued. "We then blend that with a solutions-oriented approach to help our clients overcome significant challenges to ensure that the process for their candidate is robust, compliant, economical, and scalable."

"We are proud to help advance the treatment for this growing public health concern because we're confident in the expertise that our highly skilled scientists have developed in the areas of ADCs and PDCs, based on the successful work that we have done with over 400 client projects over the last 24 plus years," said Karl Pinto, Chief Executive Officer at Goodwin Biotechnology, Inc. "Our Bioconjugation capabilities complement our experience in successfully developing and manufacturing monoclonal antibodies, recombinant proteins, and vaccines through mammalian cell culture expression systems. So, as part of our Single Source Solution, Goodwin is uniquely qualified to partner with our clients to meet their needs by developing customized and flexible approaches for manufacturing antibodies and recombinant proteins, for example, and / or design the appropriate conjugation activities to cost effectively deliver their product candidates on time."

About the Minneapolis Medical Research Foundation

The Minneapolis Medical Research Foundation (MMRF) is a subsidiary of Hennepin Healthcare System, Inc., and operates as the research arm of Hennepin County Medical Center, an acute care research and teaching hospital in Minneapolis. MMRF is one of the largest nonprofit medical research organizations in Minnesota and consistently ranks in the top 10 percent of all institutions receiving research funding from the National Institutes of Health. To learn more, visit mmrf.org.

About Goodwin Biotechnology, Inc.

Goodwin Biotechnology is a uniquely qualified CDMO that offers a Single Source Solution for our clients from cell line development (through our strategic partner), exploratory proof of concept projects through process development and cGMP contract manufacturing of monoclonal antibodies, recombinant proteins, vaccines, and Biologic Drug Conjugates including Antibody:Drug Conjugates (ADCs) for early and late stage clinical trials. By working with Goodwin Biotechnology, clients can enhance the value of their product candidates with clear development and manufacturing strategies, as well as a road map to meet the appropriate quality requirements from the milligram and gram range to kilogram quantities as the product candidates move along the clinical development pathway in a cost-effective, timely, and cGMP compliant manner to enhance patients' lives. With over 20 years of experience as an independent integrated contract manufacturer, Goodwin Biotechnology has worked as a strategic partner with numerous companies of all sizes from small university spin-offs to major research institutes, government agencies and large, established and multi-national biopharmaceutical companies. Based on the impressive track record, Goodwin Biotechnology has been awarded Frost & Sullivan's Customer Value and Leadership Award for Best Practices in Mammalian Contract Manufacturing in 2014.In addition, Goodwin Biotechnology was awarded 'Best in Sector: Biopharmaceutical Contract Development & Manufacturing' at Acquisition International magazine's 2015 Sector Performance Awards. Most recently, Goodwin Biotechnology received Global Health & Pharma's award for Best for BioProcess Development & cGMP Manufacturing in 2016, and Best in Mammalian Cell Culture Process Development & cGMP Manufacturing 2017. Click here to view the press releases!Additional information may be found at http://www.GoodwinBio.com.

Funding for this study was supported by the National Institute on Drug Abuse of the National Institutes of Health under Award Number U01DA038876. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

For more information, please contact:

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/the-minneapolis-medical-research-foundation-selects-goodwin-biotechnology-to-help-develop-and-manufacture-two-vaccines-to-treat-opioid-addiction-300426025.html

SOURCE Goodwin Biotechnology, Inc.

http://www.goodwinbio.com

Original post:
The Minneapolis Medical Research Foundation Selects Goodwin ... - PR Newswire (press release)

Read More...

Biotechnology 2017 | Biotechnology Congress | Canada …

Monday, March 20th, 2017

Allied Academies cordially invites all the participants across the globe from leading universities, clinical research institutions, diagnostic companies and all interested to share their research experiences in the Annual Biotechnology Congress during August 17-18, 2017 in Toronto, Canada with the theme of New Scientific Developments in Biotechnology of Modern Era.

Track 1:Biochemistry & Molecular Biotechnology

Molecular biotechnology is the use of laboratory techniques to study and modify nucleic acids and proteins for applications in areas such as human and animal health, agriculture, and the environment. Molecular biotechnology results from the convergence of many areas of research, such as molecular biology, microbiology, biochemistry, immunology, genetics, and cell biology. It is an exciting field fueled by the ability to transfer genetic information between organisms with the goal of understanding important biological processes or creating a useful product.

The key drivers for molecular biology enzymes, kits and reagents market are the rising R&D expenditure by the pharmaceutical and biotech companies, and increasing public funding for life science research. The World Health Organization estimates that the total aged population may rise from 605 million in 2000 (11% of the global population) to 2 billion by 2050, accounting for 22% of the global population.

Track 2:Animal biotechnology

It improves the food we eat - meat, milk and eggs. Biotechnology can improve an animals impact on the environment. Animal biotechnology is the use of science and engineering to modify living organisms. The goal is to make products, to improve animals and to develop microorganisms for specific agricultural uses. It enhances the ability to detect, treat and prevent diseases, include creating transgenic animals (animals with one or more genes introduced by human intervention), using gene knock out technology to make animals with a specific inactivated gene and producing nearly identical animals by somatic cell nuclear transfer (or cloning).

Track 3:Biomedicine Engineering

Medicine is by means of biotechnology techniques so much in diagnosing and treating dissimilar diseases. It also gives opportunity for the population to defend themselves from hazardous diseases. The pasture of biotechnology, genetic engineering, has introduced techniques like gene therapy, recombinant DNA technology and polymerase chain retort which employ genes and DNA molecules to make a diagnosis diseases and put in new and strong genes in the body which put back the injured cells. There are some applications of biotechnology which are live their part in the turf of medicine and giving good results.

This field seeks to close the gap between engineering and medicine. It combines the design and problem solving skills of engineering with medical and biological sciences to advance health care treatment, including diagnosis, monitoring and therapy. Prominent biomedical engineering applications include the development of biocompatibleprostheses, various diagnostic and therapeutic medical devices ranging from clinical equipment to micro-implants, common imaging equipment such as MRIs and EEGs, regenerative tissue growth, pharmaceutical drugs and therapeutic biological.

Track 4:Agricultural Biotechnology

Biotechnology is being used to address problems in all areas of agricultural production and processing. This includes plant breeding to raise and stabilize yields; to improve resistance to pests, diseases and abiotic stresses such as drought and cold; and to enhance the nutritional content of foods. Modern agricultural biotechnology improves crops in more targeted ways. The best known technique is genetic modification, but the term agricultural biotechnology (or green biotechnology) also covers such techniques as Marker Assisted Breeding, which increases the effectiveness of conventional breeding.

Track 5:Food Processing & Technology

Food processing is a process by which non-palatable and easily perishable raw materials are converted to edible and potable foods and beverages, which have a longer shelf life. Biotechnology helps in improving the edibility, texture, and storage of the food; in preventing the attack of the food, mainly dairy, by the virus like bacteriophage producing antimicrobial effect to destroy the unwanted microorganisms in food that cause toxicity to prevent the formation and degradation of other toxins and anti-nutritional elements present naturally in food.

Track 6:Industrial Biotechnology

Industrial biotechnology is the application of biotechnology for industrial purposes, including industrial fermentation. The practice of using cells such as micro-organisms, or components of cells like enzymes, to generate industrially useful products in sectors such as chemicals, food and feed, detergents, paper and pulp, textiles and biofuels. Industrial Biotechnologyoffers a premier forum bridging basic research and R&D with later-stage commercialization for sustainable bio based industrial and environmental applications.

Track 7: Pharmaceutical Biotechnology

Pharmaceutical Biotechnology is the science that covers all technologies required for producing, manufacturing and registration of biological drugs.Pharmaceutical Biotechnologyis an increasingly important area of science and technology. It contributes in design and delivery of new therapeutic drugs,diagnosticagents for medical tests, and in gene therapy for correcting the medical symptoms of hereditary diseases. The Pharmaceutical Biotechnology is widely spread, ranging from many ethical issues to changes inhealthcarepractices and a significant contribution to the development of national economy.Biopharmaceuticalsconsists of large biological molecules which areproteins. They target the underlying mechanisms and pathways of a disease or ailment; it is a relatively young industry. They can deal with targets in humans that are not accessible with traditional medicines.

Track 8:Environmental biotechnology

Biotechnology is applied and used to study the natural environment. Environmental biotechnology could also imply that one tries to harness biological process for commercial uses and exploitation. The development, use and regulation of biological systems for remediation of contaminated environments and for environment-friendly processes (green manufacturing technologies and sustainable development). Environmental biotechnology can simply be described as "the optimal use of nature, in the form of plants, animals, bacteria, fungi and algae, to produce renewable energy, food, and nutrients in a synergistically integrated cycle of profit making processes where the waste of each process becomes the feedstock for another process".

Track 9:Genetic & Tissue Engineering

One kind of biotechnology is gene technology, sometimes called 'genetic engineering' or 'genetic modification', where the genetic material of living things is deliberately altered to enhance or remove a particular trait and allow the organism to perform new functions. Genes within a species can be modified, or genes can be moved from one species to another.

Tissue engineering is emerging as a significant potential alternative or complementary solution, whereby tissue and organ failure is addressed by implanting natural, synthetic, or semisynthetic tissue and organ mimics that are fully functional from the start or that grow into the required functionality. Initial efforts have focused on skin equivalents for treating burns, but an increasing number of tissue types are now being engineered, as well as biomaterials and scaffolds used as delivery systems. A variety of approaches are used to coax differentiated or undifferentiated cells, such as stem cells, into the desired cell type. Notable results include tissue-engineered bone, blood vessels, liver, muscle, and even nerve conduits. As a result of the medical and market potential, there is significant academic and corporate interest in this technology.

Track 10:Nano Biotechnology

Nano biotechnology, bio nanotechnology, and Nano biology are terms that refer to the intersection of nanotechnology and biology. Bio nanotechnology and Nano biotechnology serve as blanket terms for various related technologies. The most important objectives that are frequently found in Nano biology involve applying Nano tools to relevant medical/biological problems and refining these applications. Developing new tools, such as peptide Nano sheets, for medical and biological purposes is another primary objective in nanotechnology.

Track 11:Bioinformatics

Bioinformatics is the application of computer technology to the management of biological information. Computers are used to gather, store, analyze and integrate biological and genetic information which can then be applied to gene-based drug discovery and development. The science of Bioinformatics, which is the melding of molecular biology with computer science, is essential to the use of genomic information in understanding human diseases and in the identification of new molecular targets for drug discovery.

Track 12:Biotechnology investments and Biotechnology Grants

Every new business needs some startup capital, for research, product development and production, permits and licensing and other overhead costs, in addition to what is needed to pay your staff, if you have any.Biotechnology products arise from successful biotech companies. These companies are built by talented individuals in possession of a scientific breakthrough that is translated into a product or service idea, which is ultimately brought into commercialization. At the heart of this effort is the biotech entrepreneur, who forms the company with a vision they believe will benefit the lives and health of countless individuals. Entrepreneurs start biotechnology companies for various reasons, but creating revolutionary products and tools that impact the lives of potentially millions of people are one of the fundamental reasons why all entrepreneurs start biotechnology companies.

More:
Biotechnology 2017 | Biotechnology Congress | Canada ...

Read More...

iShares Nasdaq Biotechnology (IBB) Crosses Into Overbought Range – Business Review

Sunday, March 19th, 2017

Checking on current RSI levels on shares of iShares Nasdaq Biotechnology (IBB), the 14-day RSI is currently standing at 70.50, pushing the stock into overbought territory. RSI is a momentum oscillator that moves in a range from 0 to 100. RSI is generally used to interpret whether a stock is overbought or oversold. With iShares Nasdaq Biotechnologys RSI above 70, traders should be wary of a potential pullback. Looking a bit closer at other RSI timeframes we can see the 7-day RSI is at75.84 and the 3-day is at81.54.

Fundamental Data Now well take a look at how the fundamentals are stacking up for Avalon Minerals Ltd (AVI.AX). Fundamental analysis takes into consideration market, industry and stock conditions to help determine if the shares are correctly valued. Avalon Minerals Ltd currently has a yearly EPS of -0.01. This number is derived from the total net income divided by shares outstanding. In other words, EPS reveals how profitable a company is on a share owner basis.

Another ratio we can look at is the Return on Invested Capital or more commonly referred to as ROIC. Avalon Minerals Ltd (AVI.AX) has a current ROIC of -8.06. ROIC is calculated by dividing Net Income Dividends by Total Capital Invested.

Similar to ROE, ROIC measures how effectively company management is using invested capital to generate company income. A high ROIC number typically reflects positively on company management while a low number typically reflects the opposite.

Another key indicator that can help investors determine if a stock might be a quality investment is the Return on Equity or ROE. Avalon Minerals Ltd (AVI.AX) currently has Return on Equity of -8.06. ROE is a ratio that measures profits generated from the investments received from shareholders.

In other words, the ratio reveals how effective the firm is at turning shareholder investment into company profits. A company with high ROE typically reflects well on management and how well a company is run at a high level. A firm with a lower ROE might encourage potential investors to dig further to see why profits arent being generated from shareholder money.

Turning to Return on Assets or ROA, Avalon Minerals Ltd (AVI.AX) has a current ROA of -7.96. This is a profitability ratio that measures net income generated from total company assets during a given period. This ratio reveals how quick a company can turn its assets into profits. In other words, the ratio provides insight into the profitability of a firms assets. The ratio is calculated by dividing total net income by the average total assets.

A higher ROA compared to peers in the same industry, would suggest that company management is able to effectively generate profits from their assets. Similar to the other ratios, a lower number might raise red flags about managements ability when compared to other companies in a similar sector.

Go here to read the rest:
iShares Nasdaq Biotechnology (IBB) Crosses Into Overbought Range - Business Review

Read More...

Puma Biotechnology Inc (PBYI) Moves Higher on Volume Spike for March 17 – Equities.com

Saturday, March 18th, 2017

Market Summary Follow

Puma Biotechnology Inc is a A biopharmaceutical company

PBYI - Market Data & News

PBYI - Stock Valuation Report

Puma Biotechnology Inc (PBYI) traded on unusually high volume on Mar. 17, as the stock gained 0.91% to close at $44.15. On the day, Puma Biotechnology Inc saw 2.2 million shares trade hands on 7,459 trades. Considering that the stock averages only a daily volume of 1.19 million shares a day over the last month, this represents a pretty significant bump in volume over the norm.

Generally speaking, when a stock experiences a sudden spike in trading volume, it may be seen as a bullish signal for investors. An increase in volume means more market awareness for the company, potentially setting up a more meaningful move in stock price. The added volume also provides a level of support and stability for price advances.

The stock has traded between $73.27 and $19.74 over the last 52-weeks, its 50-day SMA is now $35.79, and its 200-day SMA $42.49. Puma Biotechnology Inc has a P/B ratio of 7.77.

Puma Biotechnology Inc is a biopharmaceutical company. It is engaged in the acquisition, development and commercialization of products to enhance cancer care.

Headquartered in Los Angeles, CA, Puma Biotechnology Inc has 160 employees and is currently under the leadership of CEO Alan H. Auerbach.

For a complete fundamental analysis analysis of Puma Biotechnology Inc, check out Equities.coms Stock Valuation Analysis report for PBYI.

Want to invest with the experts? Subscribe to Equities Premium newsletters today! Visit http://www.equitiespremium.com/ to learn more about Guild Investments Market Commentary and Adam Sarhans Find Leading Stocks today.

To get more information on Puma Biotechnology Inc and to follow the companys latest updates, you can visit the companys profile page here: PBYIs Profile. For more news on the financial markets and emerging growth companies, be sure to visit Equities.coms Newsdesk. Also, dont forget to sign-up for our daily email newsletter to ensure you dont miss out on any of our best stories.

All data provided by QuoteMedia and was accurate as of 4:30PM ET.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer

Continue reading here:
Puma Biotechnology Inc (PBYI) Moves Higher on Volume Spike for March 17 - Equities.com

Read More...

NAS Issues Report on Preparing for Future Products of Biotechnology – JD Supra (press release)

Friday, March 17th, 2017

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:

JD Supra provides users with access to its legal industry publishing services (the "Service") through its website (the "Website") as well as through other sources. Our policies with regard to data collection and use of personal information of users of the Service, regardless of the manner in which users access the Service, and visitors to the Website are set forth in this statement ("Policy"). By using the Service, you signify your acceptance of this Policy.

JD Supra collects users' names, companies, titles, e-mail address and industry. JD Supra also tracks the pages that users visit, logs IP addresses and aggregates non-personally identifiable user data and browser type. This data is gathered using cookies and other technologies.

The information and data collected is used to authenticate users and to send notifications relating to the Service, including email alerts to which users have subscribed; to manage the Service and Website, to improve the Service and to customize the user's experience. This information is also provided to the authors of the content to give them insight into their readership and help them to improve their content, so that it is most useful for our users.

JD Supra does not sell, rent or otherwise provide your details to third parties, other than to the authors of the content on JD Supra.

If you prefer not to enable cookies, you may change your browser settings to disable cookies; however, please note that rejecting cookies while visiting the Website may result in certain parts of the Website not operating correctly or as efficiently as if cookies were allowed.

Users who opt in to receive emails may choose to no longer receive e-mail updates and newsletters by selecting the "opt-out of future email" option in the email they receive from JD Supra or in their JD Supra account management screen.

JD Supra takes reasonable precautions to insure that user information is kept private. We restrict access to user information to those individuals who reasonably need access to perform their job functions, such as our third party email service, customer service personnel and technical staff. However, please note that no method of transmitting or storing data is completely secure and we cannot guarantee the security of user information. Unauthorized entry or use, hardware or software failure, and other factors may compromise the security of user information at any time.

If you have reason to believe that your interaction with us is no longer secure, you must immediately notify us of the problem by contacting us at info@jdsupra.com. In the unlikely event that we believe that the security of your user information in our possession or control may have been compromised, we may seek to notify you of that development and, if so, will endeavor to do so as promptly as practicable under the circumstances.

Except as otherwise described in this privacy statement, JD Supra will not disclose personal information to any third party unless we believe that disclosure is necessary to: (1) comply with applicable laws; (2) respond to governmental inquiries or requests; (3) comply with valid legal process; (4) protect the rights, privacy, safety or property of JD Supra, users of the Service, Website visitors or the public; (5) permit us to pursue available remedies or limit the damages that we may sustain; and (6) enforce our Terms & Conditions of Use.

In the event there is a change in the corporate structure of JD Supra such as, but not limited to, merger, consolidation, sale, liquidation or transfer of substantial assets, JD Supra may, in its sole discretion, transfer, sell or assign information collected on and through the Service to one or more affiliated or unaffiliated third parties.

This Website and the Service may contain links to other websites. The operator of such other websites may collect information about you, including through cookies or other technologies. If you are using the Service through the Website and link to another site, you will leave the Website and this Policy will not apply to your use of and activity on those other sites. We encourage you to read the legal notices posted on those sites, including their privacy policies. We shall have no responsibility or liability for your visitation to, and the data collection and use practices of, such other sites. This Policy applies solely to the information collected in connection with your use of this Website and does not apply to any practices conducted offline or in connection with any other websites.

We reserve the right to change this Policy at any time. Please refer to the date at the top of this page to determine when this Policy was last revised. Any changes to our privacy policy will become effective upon posting of the revised policy on the Website. By continuing to use the Service or Website following such changes, you will be deemed to have agreed to such changes. If you do not agree with the terms of this Policy, as it may be amended from time to time, in whole or part, please do not continue using the Service or the Website.

If you have any questions about this privacy statement, the practices of this site, your dealings with this Web site, or if you would like to change any of the information you have provided to us, please contact us at: info@jdsupra.com.

- hide

More here:
NAS Issues Report on Preparing for Future Products of Biotechnology - JD Supra (press release)

Read More...

Sam Konduros named president and CEO of SC Biotechnology Industry Organization – Greenville News

Thursday, March 16th, 2017

Sam Konduros(Photo: Provided)

Sam Konduros, a former executive director of Greenville Health Systems Research Development Corporation, was named on Monday as the new president and CEO of the S.C. Biotechnology Industry Organization.

SCBIO is a statewide, non-for-profit that represents and organizes innovators in medicine, medical devices and biomaterials.

Konduros is a currently a member of the SCBIO Board of Directors.

I greatlyappreciate the SCBIO boardspassion forservingand advancing South Carolinas rapidly growing life sciences community and industry sector, and for their vote of confidence in my leadership capabilities for the organization going forward, Konduros said in a statement.

Architecture and design firm adds new hire to Greenville office

Verizon looks to fill 100 positions at new telesales center in Greenville

Konduros, a business leader and biomedical and economic development consultant, is the founder of SK Strategies LLC, launched in 2004, and has led a number of state economic development efforts.

He was the founding president and CEO of theUpstate S.C. Alliance, and is a former chairman for the Greenville Chamber of Commerce and a former committee member of the S.C. Chamber of Commerce.

Konduros has a law degree from the University of South Carolina and an undergraduate degree from Clemson University. He is alsoa graduate of the Economic Development Institute at the University of Oklahoma.

Sams strengths in knowing the biotech sector and his deep experience in business and economic development were compelling, Erin Ford, chair of SCBIO, said in a statement. The board was won over by his vision for the growth of SCBIO.

Read or Share this story: http://grnol.co/2mJTIWt

Go here to read the rest:
Sam Konduros named president and CEO of SC Biotechnology Industry Organization - Greenville News

Read More...

College hires leader for Biotechnology Center of Excellence – Triad Business Journal

Thursday, March 16th, 2017

Triad Business Journal
College hires leader for Biotechnology Center of Excellence
Triad Business Journal
Our Biotechnology Center of Excellence will be key to Alamance County's economic development and we are excited to have an administrator with the depth and breadth of experience as Yonnie Butler, said President Algie Gatewood. His range of ...

Read more:
College hires leader for Biotechnology Center of Excellence - Triad Business Journal

Read More...

Nasdaq Composite Index Approaches Record High as Biotechnology, IT Advance – Economic Calendar

Thursday, March 16th, 2017

The Nasdaq Composite Index rose Wednesday, buoyed by broad advances at biotechnology and IT companies, after the Federal Reserve decided to raise interest rates for the second time in three meetings.

The technology-heavy index rose 0.7% to 5,900.05, its fifth advance in the last six sessions. The benchmark index settled just below all-time highs.

With the gain, the Nasdaq has returned nearly 10% for the year, outpacing the S&P 500 Index and Dow Jones Industrial Average.

A total of 2,009 companies listed on the Nasdaq reported gains, versus 888 that finished lower and 229 that went unchanged. A total of 166 companies reported new highs, versus 47 that set new lows.

Health stocks listed on the S&P 500 rose more than 1%, with pharmaceuticals, biotechnology and life sciences leading the rally. Information technology also advanced 0.6% as a sector.

Advertising

The Nasdaq Biotechnology Index rose 1.5% to 3,162.82.

The Federal Reserve raised its benchmark interest rate by a quarter point to 1% in a move that was widely anticipated by the markets. Policymakers continue to expect three rate increases this year, putting the central bank on course for two additional adjustments in 2017.

In terms of upcoming releases, the U.S. Labor Department will report on initial jobless claims on Thursday. Separately, the Commerce Department will report on housing starts and building permits. The Philadelphia Fed will also report on regional manufacturing conditions in the early morning.

See the original post:
Nasdaq Composite Index Approaches Record High as Biotechnology, IT Advance - Economic Calendar

Read More...

Ceramics artist inspired by nature, biotechnology – Jewish News of Greater Phoenix

Thursday, March 16th, 2017

Ceramist Susan Beiners work has been exhibited in China, France, the Netherlands and across the nation, but it took some persuading to get her to exhibit her creations at Temple Solels latest Art Showcase.

After some cajoling, Beiner relented and now her earlier work is on display at Temple Solel through May 31. A reception and talk featuring Beiner are scheduled for 10:30 a.m. Sunday, April 2, at Temple Solel, 6805 E. McDonald Drive, Paradise Valley.

Your current subscription does not provide access to this content. Please click the button below to manage your account.

kAmp %6>A=6 $@=6= >6>36C D:?46 a_`b[ q6:?6C 😀 2? 2DD@4:2E6 AC@76DD@C 2E pC:K@?2 $E2E6 &?:G6CD:EJD[ w6C36C86C r@==686 @7 u:?6 pCE] w6C 96D:E2?4J E@ D9@H 96C H@C< 2E $@=6= 42>6 7C@> E96 724ED E92E D96 925 ?6G6C 4@?D:56C65 5:DA=2J:?8 96C 2CE 😕 2 DJ?28@8F6 367@C6[ 2D H6== 2D E96 =2C86 D:K6 @7 96C =2E6DE 4C62E:@?D]k^Am

kAm(6 E@=5 $FD2? D96 H2D 2 EC6>6?5@FD C6D@FC46 2?5 2 A2CE @7 E96 E6>A=6 2?5 H6 H2?E65 E@ D66 96C H@C<[ D2:5 xC2 %9@>2D[ 2 >6>36C @7 E96 pCE o $@=6= 4@>>:EE66] %9:D 😀 E96 7:CDE E:>6 H6G6 925 2 46C2>:4:DE]k^Am

kAmx?DA:C65 3J E96 4C27ED >@G6>6?E[ q6:?6C 3682? 4C62E:?8 9:89=J 56E2:=65[ 2?5 2E E:>6D H9:>D:42=[ E62A@ED 😕 E96 62C=J `hh_D] p=E9@F89 D96 DE:== E@@< AC:56 :? 96C E62A@ED[ 3J a__b[ q6:?6C D2:5 D96 ?66565 2 8C62E6C 2CE:DE:4 492==6?86 2?5 >@G65 @? E@ =2C86 H2== :?DE2==2E:@?D 2?5 D4F=AEFC6D]k^Am

kAmx ;FDE 5:5?E H2?E E@ >2<6 E62A@ED 2?J>@C6[ q6:?6C D2:5] x 5:5?E 766= 2D E9@F89 E96 E62A@ED H6C6 23@FE E96 7F?4E:@?2= AC@5F4E 😕 2?J H2J] x E9:?< E96J H6C6 >@C6 23@FE 2 7@C> H:E9 H9:49 E@ >2<6 >@C6 D4F=AEFC2= @C:6?E2E:@?] p7E6C x 5:5 >J 7:CDE =2C86 H2== A:646 😕 a__b[ x 76=E x 4@F=5 8@ 7FCE96C] x 4@?D:56C E96 E62A@ED 😕 2 5:776C6?E H2J E92? x 5@ >J =2E6DE H@C<] ,%96 ?6H H@C<. :D 2 5:776C6?E >:?5D6E @7 9@H x> >2<:?8 :E[ H9J x> >2<:?8 :E 2?5 E96 :562D 369:?5 :E]k^Am

kAm%96 E9:?8D x >2<6 ?@H E2<6 2 =@E =@?86C[ 3FE E96J 2C6 >@C6 @7 2 492==6?86 2?5 x E9:?< E96J 86E 36EE6C 2?5 36EE6C H:E9 E:>6[ q6:?6C 25565] x =62C? 7C@> 6249 @?6 2?5 E@ >6 E92E 😀 H@CE9 6G6CJE9:?8]k^Am

kAm{:<6 96C E62A@ED[ 96C ?6H H@C2E6C:2=D DF49 2D A=6I:8=2DD[ 7@2> 2?5 24CJ=:4D] uC@> 272C[ E96 C6DF=ED 42? =@@< =:<6 2 82C56? @7 7=@H6CD F?E:= 4=@D6C 6I2>:?2E:@? C6G62=D E96 >2?>256[ :?5FDEC:2= 2CE:7:46 E92E C6AC6D6?ED 96C :?E6C6DE 😕 ?2EFC6 2?5 3:@E649?@=@8J]k^Am

kAm*@F 42?E E6== H92ED C62= 2?5 H92ED >256 2?J>@C6[ q6:?6C D2:5] (6 42? 8C@H 2?JE9:?8 😕 E6C>D @7 v|~D W86?6E:42==J >@5:7:65 @C82?:D>DX 2?5 E9:?8D =:<6 E92E] *@F 42? 8C@H 2?J A=2?E E@ 36 D@>6E9:?8 6=D6] %96C6 2C6 2== D@CED @7 E9:?8D E92E 2C6 36:?8 5@?6 E92E >2<6 >J H@C< D66> >@C6 C62=]k^Am

kAmsF6 E@ DA246 =:>:E2E:@?D 2E %6>A=6 $@=6=[ q6:?6C 😀 >@DE=J 6I9:3:E:?8 96C 62C=J E62A@ED]k^Am

kAmq6:?6C 😀 A2CE @7 E96 E9:C5 42==E@2CE:DED 7@C E96 pCE $9@H42D6 D6C:6D 2E %6>A=6 $@=6= D:?46 a_`a] $96 😀 ;@:?65 3J D6G6? @E96C 2CE:DED H@C<:?8 :? DF49 >65:F>D 2D 24CJ=:4D[ @:=[ A9@E@8C2A9J 2?5 A2:?E:?8] %96 2CE:DED H@C< 42? 2=D@ 36 AFC492D65[ H:E9 2 A6C46?E286 @7 E96 AC@4665D 8@:?8 E@ 7F?5 2? 2CE D49@=2CD9:A 2H2C565 2??F2==J E@ 2 E6>A=6 >6>36C 9:89 D49@@= D6?:@C]k^Am

kAm(6G6 366? C62==J 3=6DD65 92G:?8 D@ >2?J %6>A=6 $@=6= >6>36CD H:E9 D@ >2?J 5:G6CD6 <:?5D @7 E2=6?ED E2=6?ED E92E D@>6 @7 E96> 5@?E 6G6? C64@8?:K6 E96>D6=G6D[ %9@>2D D2:5] |6>36CD @7 @E96C DJ?28@8F6D 92G6 G:D:E65 %6>A=6 $@=6= E@ D66 E96 G2C:@FD pCE $9@H42D6D] %9@>2D 9@A6D E92E :?E6C6DE H:== 3=@DD@> :?E@ D@>6E9:?8 3:886C]k^Am

kAm(6C6 C62==J 9@A:?8 E92E 5@H? E96 C@25 H6 42? 86E 2? 2CE 4@>>F?:EJ H:E9:? E96 #67@C> 4@?8C682E:@?D 😕 E96 '2==6J[ 96 D2:5]k^Am

Janet Perez is a freelance writer based in Phoenix.

View post:
Ceramics artist inspired by nature, biotechnology - Jewish News of Greater Phoenix

Read More...

Page 58«..1020..57585960..70..»


2025 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick